Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.87 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.87 |
| ▸ | NPC1 | O15118 | 2/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.86 |
| ▸ | RAB9A | P51151 | 2/20 | 0.86 |
| ▸ | XBP1 | P17861 | 1/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | CRHBP | P24387 | 1/20 | 0.78 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RAP1A | P62834 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Bungarotoxin SCHEMBL14043478 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| Alpha-Bungarotoxin SCHEMBL29386702 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| Brevetoxin B SCHEMBL869360 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| Alpha-Bungarotoxin SCHEMBL29374938 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| Alpha-Bungarotoxin SCHEMBL14106557 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| Alpha-Bungarotoxin SCHEMBL29381923 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| SCHEMBL15502881 | 0.94 | ALDH1A1 (0.89) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| SCHEMBL12908959 | 0.93 | ALDH1A1 (0.91) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| SCHEMBL10159481 | 0.93 | ALDH1A1 (0.91) | SCN1ASCN2ASCN3AALDH1A1NPSR1 | |
| SCHEMBL10130542 | 0.93 | ALDH1A1 (0.87) | SCN1ASCN2ASCN3AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226839-A2 | AUF1 COMPOSITIONS AND METHODS FOR PROMOTING GENERATION OF NEUROMUSCULAR JUNCTIONS | NEW YORK UNIVERSITY (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | claimed |
| CN-119506289-A | Aptamer combination suitable for single-cell sequencing and application of aptamer combination in construction of biliary tract cancer cell patterns | 中国科学院杭州医学研究所 | 2025-02-25 | — | — | CN | claimed |
| CN-119212689-A | Nicotinic acetylcholine receptor antagonists/blockers for increasing dopamine | 张燕峰 | 2024-12-27 | — | — | CN | claimed |
| EP-4479421-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | Trames Bio, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| CN-119137143-A | Ligand-gated ion channels and methods of use thereof | 特拉梅斯生物股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| EP-4319816-A1 | ANTI-VENOM ANTIBODIES AND USES THEREOF | Centivax, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| WO-2023209212-A1 | NEUTRALISATION OF α-NEUROTOXINS USING HUMAN RECOMBINANT IGG ANTIBODIES | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-02 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| CN-114354525-B | Alpha-bungarotoxin detection probe and method for detecting alpha-bungarotoxin for non-diagnostic purpose | 云南大学 | 2023-09-05 | — | — | CN | claimed |
| WO-2023159247-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | TRAMES BIO, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2022217116-A1 | ANTI-VENOM ANTIBODIES AND USES THEREOF | CENTIVAX, INC. (US) | 2022-10-13 | — | — | WO | claimed |
| CN-114354525-A | Alpha-bungarotoxin detection probe and method for detecting alpha-bungarotoxin in non-diagnosis purpose | 云南大学 | 2022-04-15 | — | — | CN | claimed |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4746855-A1 | FORMULATIONS AND USES OF ROCK2 INHIBITORS FOR ALS | Graviton Bioscience BV (NL) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104987-A1 | REMIBRUTINIB FOR USE IN THE TREATMENT OF MYASTHENIA GRAVIS | NOVARTIS AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| EP-3946411-A1 | COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES | The Trustees of Columbia University in the City of New York (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11236360-B2 | Adeno-associated viruses engineered for selectable tropism | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-02-01 | — | — | US | disclosed |
| US-11235005-B2 | Primed muscle progenitor cells and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | SCN1A 72/4885SCN2A 95/4885SCN3A 47/4885 |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | CPT1B, HPGD, PTGES | SCN1A 2795/4885SCN2A 2899/4885SCN3A 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.